Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

Clinical Trial OPEN
Bielekova, Bibiana;
  • Publisher: nct

Objective: The primary goal of this study is to define the safety and efficacy of combined systemic and intrathecal (IT) B cell-depleting therapy (i.e. anti-CD20, rituximab) in patients with secondary-progressive multiple sclerosis (SP-MS). The secondary goals of this s... View more
Share - Bookmark

  • Download from
    OpenTrials via OpenTrials (Clinical Trial)
  • Cite this research data